Equity Overview
Price & Market Data
Price: $1.25
Daily Change: +$0.02 / 1.60%
Daily Range: $1.19 - $1.26
Market Cap: $2,823,268
Daily Volume: 61,362
Performance Metrics
1 Week: -16.61%
1 Month: -41.34%
3 Months: -36.27%
6 Months: -78.87%
1 Year: -92.30%
YTD: -80.19%
Company Details
Employees: 35
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.